Liquid Biopsy

ccfDNA FAQ

Top FAQs on circulating cell-free DNA (ccfDNA) analysis

Healthcare research has been moving towards finding new, noninvasive procedures – commonly referred to as “liquid biopsies” – to replace our current protocols for diagnosis and treatment monitoring. Current protocols have tended to be overly invasive, posing health risks to the patient and decreasing quality of life. This movement has been very prevalent in the… Read article →


Heartcell_Bubbles_580x200

Exosomes in cardiovascular diseases – good or bad?

Exosomes and other extracellular vesicles (EVs) are key mediators of intercellular communication that impact the physiology of cells, tissues and organs. Exosomes participate in cellular functions, including carrying and delivering cargo such as proteins, liquids, messenger RNA (mRNA) and non-coding RNA (ncRNA). Due to their ability to circulate freely in body fluids and provide a… Read article →


SlideShare_LabBench_LiquidBiopsy_700x233

Liquid biopsy resources on SlideShare

QIAGEN offers a complete, efficient and streamlined workflow to empower your liquid biopsy research. We have added our newest webinar presentations and videos covering circulating cell-free DNA, circulating tumor cells and exosomes to SlideShare. Whether you want to learn how to collect and stabilize blood samples, discover a complete and efficient workflow for ccfDNA analysis,… Read article →


5316_NGS_QIAseq_cfDNA_700x233

A 4-part webinar series on cfDNA in liquid biopsy

Integrated collection, stabilization and purification for the cfDNA workflow Facing challenges in your circulating cell-free DNA (cfDNA) analysis? We have everything you need to gain deep insight into cfDNA: a complete and streamlined workflow covering blood sample collection and stabilization, cfDNA isolation, sequencing analysis and data interpretation. Attend the 4-part webinar series to learn about new technologies. See… Read article →


10TopCTCsFAQs_700x233

Top 10 FAQs on circulating tumor cells

During the past 20 years, the interest in circulating tumor cells (CTCs) has increased dramatically due to their potential as circulating biomarkers in monitoring cancer progression and treatment. However, selecting and detecting CTCs from whole blood of cancer patients in the background of normal cells is very challenging. Since last summer, Dr. Siegfried Hauch, Director… Read article →